- Home
- BLNK vs NRXS Comparison
BLNK vs NRXS Comparison
Compare BLNK & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLNK | NRXS |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 78.9M |
| IPO Year | 2008 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BLNK | NRXS |
|---|---|---|
| Price | $0.54 | $6.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $1.95 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.8M | 227.3K |
| Earning Date | 03-26-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.94 | 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $126,197,000.00 | $3,569,282.00 |
| Revenue This Year | N/A | $142.91 |
| Revenue Next Year | $17.87 | $120.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $0.54 | $1.33 |
| 52 Week High | $2.65 | $7.97 |
Technical Indicators
Market Signals| Indicator | BLNK | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 38.31 | 55.82 |
| Support Level | $0.54 | $5.77 |
| Resistance Level | $0.72 | $7.97 |
| Average True Range (ATR) | 0.05 | 0.69 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 2.58 | 43.59 |
Price Performance
Historical ComparisonAbout BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).